select a format

Single User License
USD 3500 INR 227570
Site License
USD 7000 INR 455140
Corporate User License
USD 10500 INR 682710

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Metabotropic Glutamate Receptor 5 mGluR5 or GRM5 or GPRC1E or MGLUR5-Pipeline Review, H1 2016

Metabotropic Glutamate Receptor 5 mGluR5 or GRM5 or GPRC1E or MGLUR5-Pipeline Review, H1 2016


  • Products Id :- GMDHC0088TDB
  • |
  • Pages: 87
  • |
  • June 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5)-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5)-Pipeline Review, H1 2016', provides in depth analysis on Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) targeted pipeline therapeutics.

The report provides comprehensive information on the Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5)

The report reviews Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) targeted therapeutics and enlists all their major and minor projects

The report assesses Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) Overview 9

Therapeutics Development 10

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5)-Products under Development by Stage of Development 10

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5)-Products under Development by Therapy Area 11

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5)-Products under Development by Indication 12

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5)-Pipeline Products Glance 14

Late Stage Products 14

Early Stage Products 15

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5)-Products under Development by Companies 16

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5)-Products under Development by Universities/Institutes 18

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5)-Therapeutics Assessment 20

Assessment by Monotherapy/Combination Products 20

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 24

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5)-Companies Involved in Therapeutics Development 25

Addex Therapeutics Ltd 25

Confluence Pharmaceuticals LLC 26

Eisai Co., Ltd. 27

Eli Lilly and Company 28

Heptares Therapeutics Limited 29

Hua Medicine (Shanghai) Ltd. 30

Johnson & Johnson 31

Medgenics, Inc. 32

Merz Pharma GmbH & Co. KgaA 33

Novartis AG 34

Sumitomo Dainippon Pharma Co., Ltd. 35

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5)-Drug Profiles 36

acamprosate calcium-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

alloswitch-1-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

dipraglurant ER-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

dipraglurant IR-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

DSR-98776-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

fasoracetam-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

GET-73-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

HTL-14242-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

JNJ-46778212-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

LSN-2463359-Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

LSN-2814617-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

mavoglurant-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

MRZ-8676-Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Small Molecule to Agonize Metabotropic Glutamate Receptor 5 for Cognitive Disorders-Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Small Molecule to Antagonize mGlu5 for Pain-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Small Molecule to Antagonize mGluR5 and mGluR6 for Neurological Disorders-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Small Molecule to Antagonize mGluR5 for CNS Disorders-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders-Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

Small Molecules to Antagonize mGluR5 for Dyskinesia-Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Small Molecules to Target mGluR5 for Schizophrenia-Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

VU-0092273-Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

VU-0431316-Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

VU-0463841-Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

VU-0467558-Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5)-Dormant Projects 66

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5)-Discontinued Products 70

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5)-Featured News & Press Releases 72

Jun 02, 2016: Addex Dipraglurant Positive Phase 2 Data in PD-LID Published in Leading Peer Reviewed Journal of the Movement Disorder Society 72

Apr 11, 2016: Addex Reports Positive Results of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers 73

Mar 15, 2016: Addex Reports Successful Completion of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers 74

Jan 11, 2016: Addex Dipraglurant Shows Highly Statistically Significant Anti-Dyskinetic Effects Following Additional Analysis of Data from the PD-LID Phase II Proof of Concept 75

Jan 04, 2016: Addex' Dipraglurant Receives Orphan Drug Designation from the FDA for Levodopa-Induced Dyskinesia Associated with Parkinson's Disease 76

Dec 17, 2015: Addex Reports Statistically Significant Positive Interim Data for Dipraglurant in Healthy Volunteer mGlu5 Receptor Occupancy Trial 76

Aug 14, 2015: Addex Dipraglurant Demonstrates Anxiolytic- and Antidepressant-like Activity in Multiple Preclinical Models Relevant for Non-Motor Symptoms in Parkinson's disease 78

Jul 22, 2015: Addex Dipraglurant Dosed in First Subject in Receptor Occupancy Study in Collaboration with Johns Hopkins University and with Funding from The Michael J. Fox Foundation 78

Feb 23, 2015: Addex Initiates Dipraglurant Receptor Occupancy Clinical Study in Collaboration with Johns Hopkins University with Funding from The Michael J. Fox Foundation 79

Jan 19, 2015: Addex and Dystonia Medical Research Foundation Announce Partnership to Explore the Therapeutic use of Dipraglurant in the Treatment of Dystonia 80

Sep 04, 2013: Chronic treatment with Addex Dipraglurant Rescues Impairment of Long-Term Synaptic Plasticity in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 81

May 01, 2013: Addex's Dipragluant Demonstrates Dose-dependent mGlu5 Receptor Occupancy In Non-human Primate PET Study 82

Apr 22, 2013: Addex Obtains European Composition Of Matter Patent Covering Dipraglurant And Other mGlu5 Negative Allosteric Modulators 83

Apr 18, 2013: Addex's Dipraglurant Normalizes Striatal Cholinergic Dysfunction In Validated Preclinical Model Of Primary Generalized Torsion Dystonia 1 84

Mar 21, 2013: Addex Therapeutics Announces Presentation On Dipraglurant Phase IIa Study Results At 2013 Annual Meeting Of American Academy Of Neurology 85

Appendix 86

Methodology 86

Coverage 86

Secondary Research 86

Primary Research 86

Expert Panel Validation 86

Contact Us 86

Disclaimer 87

List of Figures

Number of Products under Development for, H1 2016 10

Number of Products under Development by Therapy Area, H1 2016 11

Number of Products under Development by Top 10 Indication, H1 2016 12

Comparative Analysis by Late Stage Development, H1 2016 14

Comparative Analysis by Early Stage Products, H1 2016 15

Assessment by Monotherapy/Combination Products, H1 2016 20

Number of Products by Mechanism of Actions, H1 2016 21

Number of Products by Stage and Mechanism of Actions, H1 2016 21

Number of Products by Stage and Routes of Administration, H1 2016 23

Number of Products by Stage and Molecule Type, H1 2016 24

List of Tables

Number of Products under Development for, H1 2016 10

Number of Products under Development by Therapy Area, H1 2016 11

Number of Products under Development by Indication, H1 2016 13

Comparative Analysis by Late Stage Development, H1 2016 14

Comparative Analysis by Early Stage Products, H1 2016 15

Number of Products under Development by Companies, H1 2016 16

Products under Development by Companies, H1 2016 17

Number of Products under Investigation by Universities/Institutes, H1 2016 18

Products under Investigation by Universities/Institutes, H1 2016 19

Assessment by Monotherapy/Combination Products, H1 2016 20

Number of Products by Stage and Mechanism of Action, H1 2016 22

Number of Products by Stage and Route of Administration, H1 2016 23

Number of Products by Stage and Molecule Type, H1 2016 24

Pipeline by Addex Therapeutics Ltd, H1 2016 25

Pipeline by Confluence Pharmaceuticals LLC, H1 2016 26

Pipeline by Eisai Co., Ltd., H1 2016 27

Pipeline by Eli Lilly and Company, H1 2016 28

Pipeline by Heptares Therapeutics Limited, H1 2016 29

Pipeline by Hua Medicine (Shanghai) Ltd., H1 2016 30

Pipeline by Johnson & Johnson, H1 2016 31

Pipeline by Medgenics, Inc., H1 2016 32

Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2016 33

Pipeline by Novartis AG, H1 2016 34

Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 35

Dormant Projects, H1 2016 66

Dormant Projects (Contd..1), H1 2016 67

Dormant Projects (Contd..2), H1 2016 68

Dormant Projects (Contd..3), H1 2016 69

Discontinued Products, H1 2016 70

Discontinued Products (Contd..1), H1 2016 71

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Addex Therapeutics Ltd

Confluence Pharmaceuticals LLC

Eisai Co., Ltd.

Eli Lilly and Company

Heptares Therapeutics Limited

Hua Medicine (Shanghai) Ltd.

Johnson & Johnson

Medgenics, Inc.

Merz Pharma GmbH & Co. KgaA

Novartis AG

Sumitomo Dainippon Pharma Co., Ltd.

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) Therapeutic Products under Development, Key Players in Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) Therapeutics, Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) Pipeline Overview, Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) Pipeline, Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com